TNFRSF11B/OPG 蛋白, Mouse (HEK293, His)

Osteoprotegerin (OPG), a TNF receptor superfamily, is expressed in many tissues including heart, kidney, liver, spleen, and bone marrow. Osteoprotegerin has osteoprotective effect and is critical in bone remodeling. Osteoprotegerin can bind to RANKL and inhibit the binding between TNFSF11 and RANKL, thereby neutralizing the RANKL function in osteoclastogenesis^[1]. OPG is also involved in multiple biological processes of cancers. TNFRSF11B/OPG Protein, Mouse (HEK293, His) is a recombinant mouse TNFRSF11B/OPG (E22-L401) with C-terminal 10*His tag, which is produced in HEK293 cell^[1][2].

骨保护素（OPG）是一种糖蛋白，属于TNF受体超家族。OPG 在除成骨细胞外的许多组织中表达，包括心脏、肾脏、肝脏、脾脏和骨髓。人骨保护素与小鼠和大鼠的氨基酸序列同一性<85%。小鼠 OX40 与大鼠^[1]有 94.5% aa 序列同一性。
骨保护素可以与 RANKL 结合，并抑制 TNFSF11 与 RANKL 之间的结合，从而中和 RANKL 在破骨细胞生成中的功能。骨保护素还可以保护大血管免受内侧钙化。在小鼠中，骨保护素参与 B 细胞成熟和有效抗体反应的产生^[1][3]。骨保护素还参与癌症的多个过程，如肿瘤存活、上皮间质转化 (EMT)、新生血管生成、侵袭和转移^[2]。
骨保护素在骨重塑中发挥着关键作用，具有骨保护作用^[1]。

Mouse

HEK293

C-10*His

O08712 (E22-L401)

18383  [NCBI]

ETLPPKYLHYDPETGHQLLCDKCAPGTYLKQHCTVRRKTLCVPCPDHSYTDSWHTSDECVYCSPVCKELQSVKQECNRTHNRVCECEEGRYLEIEFCLKHRSCPPGSGVVQAGTPERNTVCKKCPDGFFSGETSSKAPCIKHTNCSTFGLLLIQKGNATHDNVCSGNREATQKCGIDVTLCEEAFFRFAVPTKIIPNWLSVLVDSLPGTKVNAESVERIKRRHSSQEQTFQLLKLWKHQNRDQEMVKKIIQDIDLCESSVQRHLGHSNLTTEQLLALMESLPGKKISPEEIERTRKTCKSSEQLLKLLSLWRIKNGDQDTLKGLMYALKHLKTSHFPKTVTHSLRKTMRFLHSFTMYRLYQKLFLEMIGNQVQSVKISCL

50-65 kDa

Greater than 95% as determined by reducing SDS-PAGE.

无菌粉末.

Lyophilized from a 0.2 μm filtered solution of PBS, pH 7.4.

<1 EU/μg, determined by LAL method.

It is not recommended to reconstitute to a concentration less than 100 μg/mL in ddH₂O. For long term storage it is recommended to add a carrier protein (0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose).

Stored at -20°C for 2 years. After reconstitution, it is stable at 4°C for 1 week or -20°C for longer (with carrier protein). It is recommended to freeze aliquots at -20°C or -80°C for extended storage.

Room temperature in continental US; may vary elsewhere.

• [1]. Boyce BF, et al. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007;9 Suppl 1(Suppl 1):S1.  [Content Brief]

  [2]. Wang Y, et al. The roles of osteoprotegerin in cancer, far beyond a bone player. Cell Death Discov. 2022 May 6;8(1):252.  [Content Brief]

  [3]. Schoppet M, et al. RANK ligand and osteoprotegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002 Apr 1;22(4):549-53.  [Content Brief]

  [4]. Vanderkerken K, et al. Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma. Cancer Res. 2003 Jan 15;63(2):287-9.  [Content Brief]

  [5]. Ashcroft AJ, et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. Immunity. 2003 Dec;19(6):849-61.  [Content Brief]